Last reviewed · How we verify
TY-9591
TY-9591 is a small molecule that targets the SGLT2 receptor.
TY-9591 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | TY-9591 |
|---|---|
| Also known as | C14 TY-9591, TY-9591 Tablets, placebo TY-9591 Tablets |
| Sponsor | TYK Medicines, Inc |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, TY-9591 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
Key clinical trials
- Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation (PHASE2)
- Studies Evaluating the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of TY-9591 Tablets in Healthy Subjects (PHASE1)
- A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC (PHASE2)
- [14 C] Study on Mass Balance of TY-9591 in Healthy Chinese Subjects (PHASE1)
- TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases (PHASE2)
- Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO) (PHASE3)
- A Study of TY-9591 in Advanced Non-small Cell Lung Cancer(NSCLC) Patients With EGFR Positive Mutation (PHASE1)
- A Study to Assess the Effect of Food on the Pharmacokinetics of TY-9591 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TY-9591 CI brief — competitive landscape report
- TY-9591 updates RSS · CI watch RSS
- TYK Medicines, Inc portfolio CI